ANRO ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Alto Neuroscience, Inc. Investment
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Alto Neuroscience, Inc. (NYSE:ANRO) for potential violations of federal securities laws after a failed Phase 2b study of ALTO-100 for major depressive disorder.
November 06, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alto Neuroscience, Inc. is under investigation by Levi & Korsinsky for potential securities law violations following the failure of its Phase 2b study of ALTO-100 for major depressive disorder.
The investigation by Levi & Korsinsky into potential securities law violations is likely to negatively impact investor confidence in Alto Neuroscience. The failure of the Phase 2b study of ALTO-100, a key product, further exacerbates the situation, potentially leading to a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100